Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Binocrit

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Biosimilars are biological medicines that are approved via stringently defined regulatory pathways on the basis that comparable… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
Is this relevant?
2017
2017
Erythropoietin (EPO) is one of the main therapeutics used to treat anemic patients, greatly improving their quality of life. In… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Background: Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and a risk… Expand
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2014
2014
BACKGROUND The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis… Expand
  • table 1
  • table 3
  • table 4
Is this relevant?
2012
2012
AIM To evaluate the effectiveness of a biosimilar erythropoiesis-stimulating agent (Binocrit) for the treatment of patients with… Expand
Is this relevant?
2012
2012
The aim of this study was to develop an integrated pharmacokinetic and pharmacodynamic (PK/PD) model and assess the comparability… Expand
  • figure 1
  • figure 2
  • table II
  • figure 3
  • figure 4
Is this relevant?
2012
2012
AimsThere are concerns that biosimilar erythropoiesis-stimulating agents (ESAs) are less effective than the originator ESAs. The… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
ABSTRACTPurposeTo compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to… Expand
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
OBJECTIVE To compare the steady-state pharmacokinetics and pharmacodynamics following multiple subcutaneous administration of a… Expand
Is this relevant?